Evaxion concludes Annual General Meeting
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) held its Annual General Meeting on April 16, 2026 at its Copenhagen offices. The 2025 Annual Report was approved and the Board proposals passed. Four directors were re-elected and one new director, Jens Bitsch Nørhave, was elected. Minutes are available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – EVAX
On the day this news was published, EVAX declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +19.1% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.8x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Two biotech peers (e.g., LSTA, NXTC) appeared on the momentum scanner, both moving down with median change around the low double digits, while EVAX stayed flat on the day. This points to broader biotech volatility, but EVAX’s price was largely unchanged around this governance-focused news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Clinical update EVX-01 | Positive | +2.0% | Phase 2 EVX‑01 one-year extension completed with strong response durability. |
| Mar 30 | AI vaccine presentations | Positive | +7.1% | AI-based polio and CMV vaccine data showcased at World Vaccine Congress. |
| Mar 19 | AGM convening notice | Neutral | +5.8% | Announcement of upcoming Annual General Meeting and availability of materials. |
| Mar 17 | AACR data plans | Positive | -1.3% | Acceptance of EVX‑01 and AI-Immunology™ data for AACR presentations. |
| Mar 05 | Earnings and business update | Positive | +9.3% | Full-year 2025 results, EVX‑01 data, new candidates and extended cash runway. |
EVAX has generally shown positive alignment between news flow and price, with strong reactions to clinical, partnership and earnings updates, and occasional divergences even on favorable scientific news.
Over the last six weeks, Evaxion reported multiple clinically and strategically important updates. On Mar 5, full-year 2025 results and business updates, including partnerships and cash into H2 2027, coincided with a 9.32% gain. Subsequent AACR and World Vaccine Congress announcements drew mixed but mostly positive reactions, as did the phase 2 EVX‑01 extension data on Apr 7. The prior AGM notice on Mar 19 sparked a price increase, so today’s completion of the AGM represents continuity in that governance process rather than a new clinical or financial catalyst.
Market Pulse Summary
This announcement confirms the completion of Evaxion’s Annual General Meeting, with the 2025 Annual Report approved and the existing board largely re-elected alongside one new director. It represents continuity in governance rather than a new clinical or financial catalyst. In context of recent EVX‑01 data, conference presentations, and the latest full-year results, investors may monitor future updates on clinical milestones, partnership activity, and any strategic changes stemming from the refreshed board structure.
AI-generated analysis. Not financial advice.
COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company’s offices.
The 2025 Annual Report was approved and the Board of Directors’ proposals passed.
Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected to the Board of Directors. Jens Bitsch Nørhave was elected to the Board of Directors.
Minutes from the meeting can be found on our website.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About
Evaxion Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, 2 including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
